Physician profile
Allen Nimetz
NPI 1003881871
$1,406.53
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $191.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $178.20 | 2019 | |
| Pfizer INC. | $148.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.45 | 2019 | |
| Amgen INC. | $123.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $106.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $84.89 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $72.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $51.93 | 2019 | |
| Amarin Pharma, INC. | $51.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $44.13 | 2019 | |
| Boston Scientific Corporation | $35.75 | 2019 | |
| Gilead Sciences, INC. | $28.17 | 2019 | |
| Edwards Lifesciences Corporation | $27.00 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $16.83 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.61 | 2019 | |
| Atricure, INC. | $13.25 | 2019 | |
| Bardy Diagnostics, INC. | $12.72 | 2019 | |
| Ge Healthcare | $12.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Nimetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.